TY - JOUR
T1 - HspBP1 levels are elevated in breast tumor tissue and inversely related to tumor aggressiveness
AU - Souza, Ana Paula
AU - Albuquerque, Caroline
AU - Torronteguy, Carolina
AU - Frasson, Antonio
AU - Maito, Fabio
AU - Pereira, Luciana
AU - Da Silva, Vinicius Duval
AU - Zerwes, Felipe
AU - Raynes, Deborah
AU - Guerriero, Vince
AU - Bonorino, Cristina
N1 - Funding Information:
Acknowledgements We wish to thank the patients that consented to participate in this study; Tiago Giuliane Lopes in the Pathology Department for the expert technical support with the histology studies; Dr. Moises Evandro Bauer for statistical support. Also, we wish to thank the financial support from FAPERGS, CNPq and the National Institute of General Medical Sciences (GM072628–02 (V.G.)).
Funding Information:
This work was supported by FAPERGS, CNPq, and the National Institute of General Medical Sciences grant number GM072628-02 (V.G.) The expression of HspBP1 (an Hsp70 co-chaperone) was analyzed in tumor samples and sera from breast cancer patients. HspBP1 is over expressed in these tumors and a seven year follow-up analysis found an association with a poor prognosis. Chaperones have been shown to play important roles in tumor biology and immunology; therefore, we believe the data in this study will serve as a basis for the formulation of a new hypothesis on chaperone-co-chaperone interactions and their role in tumor growth. A.P.Souza.C.Albuquerque.C.Torronteguy.F.Maito. L. Pereira.C. Bonorino (*) Faculdade de Biociências e Instituto de Pesquisas Biomédicas, PUCRS, Av. Ipiranga, 6690 2o andar, 90610-000 Porto Alegre, RS, Brazil e-mail: cbonorino@pucrs.com.br
PY - 2009/5
Y1 - 2009/5
N2 - HspBP1 is a co-chaperone that binds to and regulates the chaperone Hsp70 (Hsp70 is used to refer to HSPA1A and HSPA1B). Hsp70 is known to be elevated in breast tumor tissue, therefore the purpose of these studies was to quantify the expression of HspBP1 in primary breast tumors and in serum of these patients with a follow-up analysis after 6 to 7 years. Levels of HspBP1, Hsp70, and anti-HspBP1 antibodies in sera of breast cancer patients and healthy individuals were measured by enzyme-linked immunosorbent assay. Expression of HspBP1 was quantified from biopsies of tumor and normal breast tissue by Western blot analysis. The data obtained were analyzed for association with tumor aggressiveness markers and with patient outcome. The levels of HspBP1 and Hsp70 were significantly higher in sera of patients compared to sera of healthy individuals. HspBP1 antibodies did not differ significantly between groups. HspBP1 levels were significantly higher in tumor (14.46 ng/μg protein, n=51) compared to normal adjacent tissue (3.17 ng/μg protein, n= 41, p<0.001). Expression of HspBP1 was significantly lower in patients with lymph node metastasis and positive for estrogen receptora. HspBP1 levels were also significantly lower in patients with a higher incidence of metastasis and death following a 6 to 7-year follow-up. The HspBP1/Hsp70 molar ratio was not associated with the prognostic markers analyzed. Our results indicate that low HspBP1 expression could be a candidate tumor aggressiveness marker.
AB - HspBP1 is a co-chaperone that binds to and regulates the chaperone Hsp70 (Hsp70 is used to refer to HSPA1A and HSPA1B). Hsp70 is known to be elevated in breast tumor tissue, therefore the purpose of these studies was to quantify the expression of HspBP1 in primary breast tumors and in serum of these patients with a follow-up analysis after 6 to 7 years. Levels of HspBP1, Hsp70, and anti-HspBP1 antibodies in sera of breast cancer patients and healthy individuals were measured by enzyme-linked immunosorbent assay. Expression of HspBP1 was quantified from biopsies of tumor and normal breast tissue by Western blot analysis. The data obtained were analyzed for association with tumor aggressiveness markers and with patient outcome. The levels of HspBP1 and Hsp70 were significantly higher in sera of patients compared to sera of healthy individuals. HspBP1 antibodies did not differ significantly between groups. HspBP1 levels were significantly higher in tumor (14.46 ng/μg protein, n=51) compared to normal adjacent tissue (3.17 ng/μg protein, n= 41, p<0.001). Expression of HspBP1 was significantly lower in patients with lymph node metastasis and positive for estrogen receptora. HspBP1 levels were also significantly lower in patients with a higher incidence of metastasis and death following a 6 to 7-year follow-up. The HspBP1/Hsp70 molar ratio was not associated with the prognostic markers analyzed. Our results indicate that low HspBP1 expression could be a candidate tumor aggressiveness marker.
KW - Breast cancer
KW - Co-chaperone
KW - Hsp70
KW - Hspbp1
KW - Prognostic markers
UR - http://www.scopus.com/inward/record.url?scp=66149150652&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=66149150652&partnerID=8YFLogxK
U2 - 10.1007/s12192-008-0085-6
DO - 10.1007/s12192-008-0085-6
M3 - Article
C2 - 18987994
AN - SCOPUS:66149150652
VL - 14
SP - 301
EP - 310
JO - Cell Stress and Chaperones
JF - Cell Stress and Chaperones
SN - 1355-8145
IS - 3
ER -